E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Influenza Vaccination in healthy subjects |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the safety and tolerability of a Split Virus Vero Cell Derived, Seasonal Influenza Vaccine in comparison to an egg derived vaccine in two age strata 18 to 49 years of age and 50 years of age and older.
To assess the immunogenicity of a Split Virus Vero Cell Derived, Seasonal Influenza Vaccine in comparison to an egg derived vaccine in two age strata 18 to 49 years of age and 50 years of age and older. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Male and female subjects will be eligible for participation in this study if they: - Are 18 to 49 years of age, inclusive, on the day of screening (Stratum A) - Are 50 years of age or older on the day of screening (Stratum B) - Have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry - Are clinically healthy (in a physical condition such that the physician would have no reservations administering influenza vaccine outside the scope of a clinical study) - Are physically and mentally capable of participating in the study - Agree to keep a daily record of symptoms - If female and capable of bearing children – have a negative urine pregnancy test result within 24 hours of the vaccination on Study Day 0 and agree to employ adequate birth control measures. For the purposes of this study adequate birth control measures incorporate two types of the following FDA approved birth control measures through 60 days after the vaccination. - Hormonal types of birth control (such as implants, birth control pills, patches or other methods) or an intrauterine device, AND - An additional barrier type of birth control measure (i.e., condoms, diaphragms, cervical caps, etc.).
|
|
E.4 | Principal exclusion criteria |
Subjects will be excluded from this study if they: - Have previously been vaccinated against influenza with vaccine formulated for the 2006/2007 influenza season - Have an oral temperature of 37.5 C at the time of vaccination on Day 0* (See Note Below)* - Have Type I diabetes - Have a Body Mass Index > 35 - Have hypertension at screening (with or without medication) that is graded as greater than Stage 1 defined as a systolic pressure > 159 or diastolic pressure > 99 while seated and at rest (Measurement may be repeated twice before subject is absolutely excluded) - Have clinically significant abnormal clinical laboratory values at screening - Have clinically significant electrocardiographic abnormalities at screening - Test positive for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HbsAg) or Hepatitis C Virus (HCV) - Have a history of cardiovascular disease that required hospitalization - Have a history of immunodeficiency or autoimmune diseases - Have a history of arthritis (joint swelling, tenderness, warmth or erythema) on more than one occasion, not related to trauma (including running) or any episode of non-trauma related arthritis within the previous 6 months; - Suffer from active neoplastic disease or have a history of hematologic malignancy - Suffer from a disease or are undergoing a form of treatment that can be expected to influence immune response. Such treatment includes, but is not limited to systemic or high dose inhaled (>800 µg/day of beclomethasone dipropionate or equivalent) cortico-steroids, radiation treatment or other immunosuppressive or cytotoxic drugs - Have a history of inflammatory or degenerative neurological disease (e.g. Guillain Barré, multiple sclerosis) - Have received any vaccination within 2 weeks prior to vaccination in this study - Have received a blood transfusion or immunoglobulins within 30 days prior to vaccination in this study - Have donated blood or plasma within 30 days prior to vaccination in this study - Have a history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to eggs, allergy to components of the test or comparator vaccine, other known contraindications) - Have a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating - Have a positive urine drug screen, (Unless the detected drug is currently prescribed by a licensed health care provider and the continued administration of the drug would not otherwise exclude the subject from participation) - Were administered an investigational drug within six weeks prior to study entry - Are concurrently participating in a clinical study that includes the administration of an investigational product - Are a member of the team conducting this study - re in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator - If female, are pregnant or lactating. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary end point is the number of subjects in each vaccine group with oral temperatures greater or equal to 38°C and onset within 2 days after vaccination. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Vaxigrip 2006/2007 (Aventis Pasteur) |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
This study is terminated when the last subject in Cohort 2 completes the Day 180 visit. The study may be prematurely terminated if SAEs or ohter significant vaccine related side effects occur. In addition the sponsor may stop the entire study for any reason at any time. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 7 |